Brief: Silence Therapeutics Announces Preliminary Single Dose Results From SLN124 Phase 1 Study In Patients With Thalassemia
29/09/2022 12:03
Sept 29 (Reuters) - Silence Therapeutics PLC SLNCF.PK :
* SILENCE THERAPEUTICS ANNOUNCES PRELIMINARY SINGLE DOSE
RESULTS
FROM SLN124 PHASE 1 STUDY IN PATIENTS WITH THALASSEMIA
Source text for Eikon: ID:nBw44Mz1ta
Further company coverage: SLNCF.PK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing